Restrictions commerciales pour l'importation de marchandises pour 3002510000 10
Les droits d’autres codes avec un compte gratuit
Vous avez consulté les droits de 10 codes aujourd’hui. Créez un compte gratuit pour voir droits, mesures et historique de tous les codes.
Règles d’origine préférentielles pour 3002510000
Ce que la marchandise doit remplir pour être originaire d’un pays partenaire et bénéficier du droit préférentiel, par accord. Texte des accords en anglais.
EU-Egypt Association Agreement · Égypte
EU-Lebanon Association Agreement · Liban
EU-Morocco Association Agreement · Maroc
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products:
– Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– Other
– – Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
Generalised Scheme of Preferences (GSP, GSP+, EBA) · Arménie, Îles Salomon, Inde, Kenya, Pakistan, Samoa, Syrie, Viêt Nam
EU-Singapore FTA · Singapour
Pharmaceutical products / or: Manufacture from materials of any heading
Autonomous Trade Preferences (Western Balkans) · Kosovo
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products:
- Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
- Other:
- - Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
- - Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
- - Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
- - Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
- - Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
EU-Canada CETA · Canada
A change from within any one of these subheadings or any other subheading.
EU-Chile Association Agreement · Chili
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: — Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — Other — — Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — — Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — — Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — — Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — — Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
EU-Colombia/Peru/Ecuador Trade Agreement · Colombie, Équateur, Pérou
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products:
Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product
Other:
Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product
Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product
Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product
Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product
Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product
EU-Algeria Association Agreement · Algérie
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of microorganisms (excluding yeasts) and similar products:
– Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– Other
– – Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
– – Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
EPA CARIFORUM
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: – Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – Other: – – human blood / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – – animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – – blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – – haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – – other / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
EU Market Access Regulation (EPA) · Cameroun, Côte d’Ivoire, Ghana, Kenya
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products:
– Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packing's for retail sale / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
– Other:
– – human blood / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
– – animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
– – blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
– – haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
– – other / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
EU-Jordan Association Agreement · Jordanie
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: - Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - Other - - Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - - Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - - Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - - Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - - Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
EU-Japan EPA · Japon
CTSH; A chemical reaction, purification, mixing and blending, production of standard materials, a change in particle size, isomer separation or biotechnological processing is undergone; MaxNOM 50 % (EXW); or RVC 55 % (FOB).
EU-Korea FTA · Corée du Sud
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products. / or: Manufacture from materials of any heading
EU-Central America Association Agreement
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products,whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products / or: Manufacture from materials of any heading
EU-Mexico Global Agreement · Mexique
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: — Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — Other: — — Human blood / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — — Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — — Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — — Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — — Other / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product
EU-Palestine Interim Association Agreement · Palestine
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: - Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product - Other: -- human blood / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product -- animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product -- blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product -- haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product -- other / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product
EU-Tunisia Association Agreement · Tunisie
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product
EU-Viet Nam FTA · Viêt Nam
Pharmaceutical products. / or: Manufacture from materials of any heading.
Source : Commission européenne, Access2Markets (CC BY 4.0, abrégé). Seul le texte de l’accord fait foi. Access2Markets
Notes légales et notes explicatives pour 3002510000
Notes du chapitre 30
Notes 1. Le présent chapitre ne comprend pas: a) les aliments diététiques, aliments enrichis, aliments pour diabétiques, compléments alimentaires, boissons toniques et eaux minérales, autres que les préparations nutritives administrées par voie intraveineuse (section IV); b) les produits, tels que les comprimés, les gommes à mâcher ou les timbres ou rondelles autocollants (administrés par voie percutanée), contenant de la nicotine et destinés à aider le sevrage tabagique (no 2404); c) les plâtres spécialement calcinés ou finement broyés pour l'art dentaire (no 2520); d) les eaux distillées aromatiques et solutions aqueuses d'huiles essentielles, médicinales (no 3301); e) les préparations des nos 3303 à 3307, même si elles ont des propriétés thérapeutiques ou prophylactiques; f) les savons et autres produits du no 3401 additionnés de substances médicamenteuses; g) les préparations à base de plâtre pour l'art dentaire (no 3407); h) l'albumine du sang non préparée en vue d'usages thérapeutiques ou prophylactiques (no 3502); ij) les réactifs de diagnostic du no 3822. 2. Au sens du n° 3002, on entend par produits immunologiques les peptides et les protéines (à l’exclusion des produits du n° 2937) qui participent directement à la régulation des processus immunologiques, tels que les anticorps monoclonaux (MAB), les fragments d’anticorps, les conjugués d’anticorps et de fragments d’anticorps, les interleukines, les interférons (IFN), les chimiokines, ainsi que certains facteurs onconécrosants (TNF), facteurs de croissance (GF), hématopoïétines et facteurs de stimulation de colonies (CSF). 3. Au sens des nos 3003 et 3004 et de la note 4, point d), du chapitre, on considère: a) comme «produits non mélangés»: 1) les solutions aqueuses de produits non mélangés; 2) tous les produits des chapitres 28 ou 29; 3) les extraits végétaux simples du no 1302, simplement titrés ou dissous dans un solvant quelconque; b) comme «produits mélangés»: 1) les solutions et suspensions colloïdales (à l'exclusion du soufre colloïdal); 2) les extraits végétaux obtenus par le traitement de mélanges de substances végétales; 3) les sels et eaux concentrés obtenus par évaporation des eaux minérales naturelles. 4. Ne sont compris dans le no 3006 que les produits suivants qui devront être classés dans cette position et non dans une autre position de la nomenclature: a) les catguts stériles, les ligatures stériles similaires pour sutures chirurgicales (y compris les fils résorbables stériles pour la chirurgie ou l’art dentaire) et les adhésifs stériles pour tissus organiques utilisés en chirurgie pour refermer les plaies; b) les laminaires stériles; c) les hémostatiques résorbables stériles pour la chirurgie ou l'art dentaire; les barrières anti-adhérence stériles pour la chirurgie ou l'art dentaire, résorbables ou non; d) les préparations opacifiantes pour examens radiographiques, ainsi que les réactifs de diagnostic conçus pour être employés sur le patient et qui sont des produits non mélangés présentés sous forme de doses ou bien des produits mélangés, constitués par deux ingrédients ou davantage, propres aux mêmes usages; e) placebos et trousses pour essais cliniques masqués (ou à double insu), destinés à être utilisés dans le cadre d’essais cliniques reconnus, présentés sous forme de doses, même contenant des médicaments actifs; f) les ciments et autres produits d'obturation dentaire; les ciments pour la réfection osseuse; g) les trousses et boîtes de pharmacie garnies, pour soins de première urgence; h) les préparations chimiques contraceptives à base d'hormones, d'autres produits du no 2937 ou de spermicides; ij) les préparations présentées sous forme de gel conçues pour être utilisées en médecine humaine ou vétérinaire comme lubrifiant pour certaines parties du corps lors des opérations chirurgicales ou des examens médicaux ou comme agent de couplage entre le corps et les instruments médicaux; k) les déchets pharmaceutiques, c'est-à-dire les produits pharmaceutiques impropres à leur usage initial en raison, par exemple, du dépassement de leur date de péremption; l) les appareillages identifiables de stomie, à savoir les sacs, coupés de forme, pour colostomie, iléostomie et urostomie ainsi que leurs protecteurs cutanés adhésifs ou plaques frontales. Notes de sous-positions 1. Au sens des nos3002 13 et 3002 14, on considère: a) comme produits non mélangés, les produits purs, que ces composés contiennent ou non des impuretés; b) comme produits mélangés: 1) les solutions aqueuses et les autres solutions des produits du paragraphe a) ci-dessus; 2) les produits des paragraphes a) et b) 1) ci-dessus additionnés d’un stabilisant indispensable à leur conservation ou à leur transport; 3) les produits des paragraphes a), b) 1) et b) 2) ci-dessus additionnés d’autres additifs. 2. Les nos3003 60 et 3004 60 couvrent les médicaments contenant de l’artémisinine (DCI) pour administration par voie orale associée à d’autres ingrédients pharmaceutiques actifs, ou contenant l’un des principes actifs suivants, même associés à d’autres ingrédients pharmaceutiques actifs : de l’amodiaquine (DCI); de l’acide artélinique ou ses sels; de l’arténimol (DCI); de l’artémotil (DCI); de l’artéméther (DCI); de l’artésunate (DCI); de la chloroquine (DCI); de la dihydroartémisinine (DCI); de la luméfantrine (DCI); de la méfloquine (DCI); de la pipéraquine (DCI); de la pyriméthamine (DCI) ou de la sulfadoxine (DCI). Note complémentaire 1. Le no 3004 comprend des préparations médicinales à base de plantes et des préparations à base des substances actives suivantes: vitamines, minéraux, acides aminés essentiels et acides gras, conditionnés pour la vente au détail. Ces préparations sont à classer dans le no 3004 si l'étiquette, l'emballage ou le mode d'emploi porte les indications suivantes: a) les maladies, affections ou leurs symptômes, spécifiques, contre lesquels elles doivent être employées; b) la concentration de la substance active ou des substances actives qu'elles contiennent; c) la posologie; et d) le mode d'administration. Cette position comprend également les préparations homéopathiques à usage médical à condition qu'elles remplissent les conditions a), c) et d) mentionnées ci-dessus. Dans le cas des préparations à base de vitamines, minéraux, acides aminés essentiels et acides gras, le niveau d'une de ces substances par dose journalière recommandée figurant sur l'étiquette doit être significativement plus élevé que l'apport journalier recommandé nécessaire pour garder la santé en général ou le bien-être.
Autres notes explicatives du chapitre
Note complémentaire 1 1. Par préparations à base de plantes, on entend les préparations à base d'une ou de plusieurs substances actives produites en soumettant une plante ou des parties de celle-ci à des opérations telle que le séchage, le broyage, l'extraction ou la purification. Par substance active, on entend une substance chimiquement définie, un groupe de substances chimiquement définies (par exemple alcaloïdes, polyphénols, anthocyanines) ou un extrait de plantes. Ces substances actives doivent avoir des propriétés médicinales en vue de la prévention ou du traitement de maladies ou d'affections spécifiques ou de leurs symptômes. 2. Les préparations homéopathiques à usage médical sont obtenues à partir de produits, de substances ou de compositions appelés souches homéopathiques (teintures mères). Le degré de dilution doit être indiqué (par exemple D6). 3. Par préparations de vitamines ou de minéraux, on entend les préparations à base de vitamines du no 2936, de minéraux y compris les oligoéléments ainsi que de leurs mélanges. Elles sont utilisées pour le traitement ou la prévention de maladies ou d'affections spécifiques ou de leurs symptômes. La teneur en vitamines ou en minéraux de ce type de préparations est beaucoup plus élevée, généralement au moins trois fois plus élevée que l'apport journalier recommandé (AJR/RDA). En ce qui concerne l’apport journalier recommandé (AJR) pour certaines vitamines et certains sels minéraux, voir, par exemple, le tableau figurant à l’annexe XIII du règlement (UE) no 1169/2011 du Parlement européen et du Conseil du 25 octobre 2011 concernant l’information des consommateurs sur les denrées alimentaires (JO L 304 du 22.11.2011, p. 58), reproduit ci-après: Vitamines et sels mineraux | AJR/RDA Vitamine A | 800 μg Vitamine D | 5 μg Vitamine E | 12 mg Vitamine K | 75 μg Vitamine C | 80 mg Thiamine 1,1 mg Riboflavine | 1,4 mg Niacine 16 mg Vitamine B6 | 1,4 mg Folacine (acide folique) | 200 μg Vitamine B12 | 2,5 μg Biotine 50 μg Acide pantothénique | 6 mg Potassium | 2 000 mg Chlorure 800 mg Calcium 800 mg Phosphore | 700 mg Magnésium | 375 mg Fer 14 mg Zinc 10 mg Cuivre 1 mg Managanèse | 2 mg Fluorure 3,5 mg Sélénium 55 μg Chrome 40 μg Molybdène | 50 μg Iode 150 μg 4. Apport journalier recommandé (AJR) en acides aminés essentiels pour des adultes dont le poids corporel est de 70 kg, selon la consultation conjointe d’experts FAO/OMS/UNU de 2007: Acide aminé essentiel | AJR (mg) Histidine | 700 Isoleucine | 1 400 Leucine 2 730 Lysine 2 100 Méthionine + cystéine | 1 050 Cystéine 287 Méthionine | 728 Phénylalanine + tyrosine | 1 750 Thréonine | 1 050 Tryptophan | 280 Valine 1 820 Apport journalier recommandé (AJR) en acides gras essentiels pour des adultes dont le poids corporel est de 70 kg, selon la consultation conjointe d’experts FAO/OMS/UNU de 2007. Types d’acides gras essentiels | Nom de l’acide gras essentiel | AJR (g) acides gras polyinsaturés n-3 | acide linolénique (ALA) | 2 acides gras polyinsaturés à longue chaîne n-3 | EPA + DHA | 0,25 acides gras polyinsaturés n-6 | acide linoléique | 10
Sources : nomenclature combinée 2026, annexe I du règlement (CEE) nº 2658/87 (CELEX 32025R1926), et notes explicatives de la nomenclature combinée (CELEX 02019XC0329(02)-20260213). Les notes de section et de chapitre ont force juridique ; les notes explicatives sont une aide à l’interprétation. EUR-Lex
Renseignements tarifaires du Royaume-Uni pour 3002510000
Décisions de HM Revenue & Customs pour des marchandises dont le code britannique commence comme ce code de l’UE. Le tarif britannique diffère de celui de l’UE : ces décisions ne sont qu’une indication pour l’UE.
- UK 3002510000 Valable du 2 août 2024 au 1 août 2027 · Décision 600010909 sur GOV.UK
modified lymphocytes Use: treatment of patients, in clinical trials or commercially marketed cryopreserved for transportation and importation purposes
Justification
Classification has been determined in accordance with the following:- For the purposes of determining the commodity codes within which goods most appropriately fall, reg 3 (1) of The Customs Tariff (Establishment) (EU Exit) Regulations 2020 sets out that the rules of interpretation contained in the following have effect – a. Part Two (Goods Classification Table Rules of Interpretation) of the Tariff of the United Kingdom (Reg 3(1)(a)); and b. Notes to a section or chapter of the Goods Classification Table (Reg 3(1)(b)). General Interpretative Rules (GIR)s GIR 1 has been used to classify this product by the terms of heading 3002 - Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified GIR 5b has been used to identify the type of packaging – cryopreserved GIR 6 has been used to classify the goods to subheading level 300251 – Cell cultures, whether or not modified; Cell therapy products …
- UK 3002510000 Valable du 2 août 2024 au 1 août 2027 · Décision 600010993 sur GOV.UK
modified lymphocytes Use: treatment of patients, in clinical trials or commercially marketed cryopreserved for transportation and importation purposes
Justification
Classification has been determined in accordance with the following:- For the purposes of determining the commodity codes within which goods most appropriately fall, reg 3 (1) of The Customs Tariff (Establishment) (EU Exit) Regulations 2020 sets out that the rules of interpretation contained in the following have effect – a. Part Two (Goods Classification Table Rules of Interpretation) of the Tariff of the United Kingdom (Reg 3(1)(a)); and b. Notes to a section or chapter of the Goods Classification Table (Reg 3(1)(b)). General Interpretative Rules (GIR)s GIR 1 has been used to classify this product by the terms of heading 3002 - Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified GIR 5b has been used to identify the type of packaging – cryopreserved GIR 6 has been used to classify the goods to subheading level 300251 – Cell cultures, whether or not modified; Cell therapy products …
- UK 3002510000 Valable du 7 août 2024 au 6 août 2027 · Décision 600011117 sur GOV.UK
modified lymphocytes Use: treatment of patients, in clinical trials or commercially marketed cryopreserved for transportation and importation purposes
Justification
Classification has been determined in accordance with the following:- For the purposes of determining the commodity codes within which goods most appropriately fall, reg 3 (1) of The Customs Tariff (Establishment) (EU Exit) Regulations 2020 sets out that the rules of interpretation contained in the following have effect – a. Part Two (Goods Classification Table Rules of Interpretation) of the Tariff of the United Kingdom (Reg 3(1)(a)); and b. Notes to a section or chapter of the Goods Classification Table (Reg 3(1)(b)). General Interpretative Rules (GIR)s GIR 1 has been used to classify this product by the terms of heading 3002 - Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified GIR 5b has been used to identify the type of packaging – cryopreserved GIR 6 has been used to classify the goods to subheading level 300251 – Cell cultures, whether or not modified; Cell therapy products …
+ 1 de plus
- UK 3002510000 Valable du 7 août 2024 au 6 août 2027 · Décision 600011118 sur GOV.UK
modified lymphocytes Use: treatment of patients, in clinical trials or commercially marketed cryopreserved for transportation and importation purposes
Justification
Classification has been determined in accordance with the following:- For the purposes of determining the commodity codes within which goods most appropriately fall, reg 3 (1) of The Customs Tariff (Establishment) (EU Exit) Regulations 2020 sets out that the rules of interpretation contained in the following have effect – a. Part Two (Goods Classification Table Rules of Interpretation) of the Tariff of the United Kingdom (Reg 3(1)(a)); and b. Notes to a section or chapter of the Goods Classification Table (Reg 3(1)(b)). General Interpretative Rules (GIR)s GIR 1 has been used to classify this product by the terms of heading 3002 - Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified GIR 5b has been used to identify the type of packaging – cryopreserved GIR 6 has been used to classify the goods to subheading level 300251 – Cell cultures, whether or not modified; Cell therapy products …
Source : HM Revenue & Customs, Advance Tariff Rulings. Contient des informations du secteur public sous licence Open Government Licence v3.0.
Restrictions et signalements pour 300251
- Biens à double usage Règlement (UE) 2021/821, Annexe I 30025100
Ne couvre qu’une partie des marchandises sous ce code (l’acte cite 30025100).
Peut être à double usage ; vérifier l'entrée 1C351 de l'annexe I (table de correspondance non contraignante)
Lire l’acte sur EUR-Lex
À titre indicatif. Vérifiez l’acte avant de vous fier à un signalement ; les seuils, dérogations et exceptions ne sont pas tous indiqués. Le tableau des biens à double usage relie les codes aux entrées de la liste de contrôle et n’est pas contraignant.
Commerce de l’UE en 2025 pour 300251
- Importations extra-UE
- 662,9 M €
- 61 t
- Exportations extra-UE
- 314 M €
Principaux pays d’origine selon la valeur importée
États-Unis 490,6 M €
Suisse 149,7 M €
Royaume-Uni 21,3 M €
Chine 999,2 k €
Brésil 145,4 k €
Codes NC8 sous ce code : 1. Source : Eurostat, Comext, CC BY 4.0, traité par hscode.info. Le commerce confidentiel n’est pas attribué aux codes.
Modifications tarifaires pour 300251 depuis 2016
- janv. 2022 3002510000 Code créé
Comparaison mensuelle des extractions TARIC de la Commission européenne. Prix d’entrée saisonniers exclus.
Droit d’importation au Royaume-Uni pour 300251
- 0%
Droits de pays tiers de tous les codes britanniques sous cette sous-position du SH. Source : UK Department for Business and Trade, au 2 nov. 2026. Le tarif britannique diffère du tarif de l’UE.
TVA à l’importation dans l’UE
- Allemagne 19 %
- Autriche 20 %
- Belgique 21 %
- Bulgarie 20 %
- Chypre 19 % éventuellement 5 %
- Croatie 25 %
- Danemark 25 %
- Espagne 21 %
- Estonie 24 % éventuellement 9 %
- Finlande 25,5 %
- France 20 %
- Grèce 24 % éventuellement 6 %, 13 %
- Hongrie 27 %
- Irlande 23 %
- Italie 22 %
- Lettonie 21 % éventuellement 12 %
- Lituanie 21 % éventuellement 5 %
- Luxembourg 17 %
- Malte 18 % éventuellement 5 %
- Pays-Bas 21 %
- Pologne 23 %
- Portugal 23 %
- Roumanie 21 % éventuellement 11 %
- Slovaquie 23 % éventuellement 5 %
- Slovénie 22 % éventuellement 9,5 %
- Suède 25 %
- Tchéquie 21 % éventuellement 12 %
Taux normal par État membre, sur la valeur en douane, les droits et le transport jusqu’à destination. Les taux réduits dépendent souvent de l’usage ou de l’acheteur et ne s’appliquent que si le pays les prévoit pour ces marchandises. Source : Commission européenne, Taxes in Europe Database, au 2 nov. 2026.
Règles d’origine
Les règles d’origine préférentielles de la sous-position 300251 dépendent de l’accord commercial. La Commission les publie dans Access2Markets.
Règles d’origine sur Access2MarketsInformations
Lorsque vous importez ou exportez "Cultures de cellules, même modifiées", il est important d'avoir le bon code SH ou code TARIC. Le code HS 3002510000 10 est le code standard pour ce produit et garantit l'application des droits et taxes appropriés lorsqu'il franchit les frontières internationales.
Pour assurer un déroulement fluide de vos activités d'importation ou d'exportation de "Cultures de cellules, même modifiées", veuillez noter les points suivants :
- Informez-vous sur les régulations spécifiques à l'importation et à l'exportation dans les pays concernés. Cela comprend les restrictions, taxes et droits éventuels applicables sur "Cultures de cellules, même modifiées".
- Vérifiez si des licences, autorisations ou certificats supplémentaires sont nécessaires pour importer "Cultures de cellules, même modifiées" dans le pays de destination ou l'exporter depuis le pays d'origine.
- Assurez-vous que vos partenaires commerciaux disposent de numéros d'identification valides, tels que le numéro EORI (Economic Operators Registration and Identification) au sein de l'UE, afin de fluidifier les échanges et minimiser les retards.
- Vérifiez que tous les documents relatifs au commerce et aux douanes (facture commerciale, liste de colisage, certificats d'origine et polices d'assurance) sont correctement remplis et conformes aux régulations nationales respectives.
- Suivez les taux de change actuels ainsi que les coûts d'emballage, de transport et d'assurance afin de calculer avec précision le coût commercial.
En résumé, le code HS-Code ou le code TARIC pour "Cultures de cellules, même modifiées" est 3002510000 10. Assurez-vous d'utiliser correctement ce code dans tous vos documents commerciaux et douaniers pour garantir des transactions fluides et sans problème. Avec ces conseils, vous serez mieux préparé pour relever les défis du commerce international et réussir à importer et exporter "Cultures de cellules, même modifiées".
Structure du HS-Code
1. Chapitre
Il y a 21 sections différentes qui sont divisées en 96 chapitres. Les chapitres d'exception comprennent le chapitre 77, qui est réservé à une utilisation future, les chapitres 98 et 99, qui sont limités au niveau national, et le chapitre 99, qui est un code spécifique pour les modifications temporaires. Dans l'exemple ci-dessus, le chapitre 30 a été sélectionné pour produits pharmaceutiques
2. Titre
Le titre détermine la catégorie spécifique au sein d'un chapitre donné. Dans l'exemple ci-dessus, le 02 se réfère à Sang humain; sang animal préparé en vue d'usages thérapeutiques, prophylactiques ou de diagnostic; antisérums, autres fractions du sang et produits immunologiques, même modifiés ou obtenus par voie biotechnologique; vaccins, toxines, cultures de micro-organismes (à l'exclusion des levures) et produits similaires; cultures de cellules, même modifiées.
3. Sous-titre
Les deux derniers chiffres du code harmonisé international sont plus spécifiques et définissent des sous-catégories de produits. Dans l'exemple ci-dessus, la 51 se réfère à Cultures de cellules, même modifiées.
Arborescence HS-Code
3000000000 80
Chapitre PRODUITS PHARMACEUTIQUES
3002000000 80
Sang humain; sang animal préparé en vue d'usages thérapeutiques, prophylactiques ou de diagnostic; antisérums, autres fractions du sang et produits immunologiques, même modifiés ou obtenus par voie biotechnologique; vaccins, toxines, cultures de micro-organismes (à l'exclusion des levures) et produits similaires; cultures de cellules, même modifiées
3002120000 10
- Antisérums, autres fractions du sang et produits immunologiques, même modifiés ou obtenus par voie biotechnologique
3002120000 80
- - Antisérums et autres fractions du sang
3002130000 80
- - Produits immunologiques, non mélangés et ni présentés sous forme de doses, ni conditionnés pour la vente au détail
3002140000 80
- - Produits immunologiques, mélangés et ni présentés sous forme de doses, ni conditionnés pour la vente au détail
3002150000 80
- - Produits immunologiques, présentés sous forme de doses, ou conditionnés pour la vente au détail
3002410000 10
- Vaccins, toxines, cultures de micro- organismes (à l'exclusion des levures) et produits similaires
3002410000 80
- - Vaccins pour la médecine humaine
3002411000 80
- - - Vaccins contre les coronavirus du SRAS (espèce SARS-CoV)
3002419000 80
- - - autres
3002420000 80
- - Vaccins pour la médecine vétérinaire
3002490000 80
- - autres
3002490010 10
- - - Cultures de micro-organismes
3002490010 80
- - - - Agents pathogènes et cultures d’agents pathogènes
3002490020 80
- - - - autres
3002490081 10
- - - autres
3002490081 80
- - - - Agents pathogènes et cultures d’agents pathogènes
3002490089 80
- - - - autres
3002510000 10
- Cultures de cellules, même modifiées
3002510000 80
- - Produits de thérapie cellulaire
3002590000 80
- - autres
3002900000 80
- autres
3002901000 80
- - Sang humain
3002903000 80
- - Sang animal préparé en vue d'usages thérapeutiques, prophylactiques ou de diagnostic